Gastroesophageal Reflux Disease Therapeutics Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Gastroesophageal Reflux Disease Therapeutics Market Growth in 2025?
The market for therapeutics for gastroesophageal reflux disease has experienced consistent expansion in the past few years. The market is forecasted to increase from $5.93 billion in 2024 to $6.14 billion in 2025, maintaining a compound annual growth rate (CAGR) of 3.6%. The escalation seen in earlier times can be linked to alterations in lifestyles and eating habits, increasing age demographics, improved understanding and diagnosis, dominant stressful living circumstances, and surging obesity figures.
What Is the Forecast for the Gastroesophageal Reflux Disease Therapeutics Market Size Through 2029?
In the coming years, the market for therapeutics related to gastroesophageal reflux disease is predicted to experience significant growth, reaching a valuation of $7.89 billion by 2029, advancing at a compound annual growth rate (CAGR) of 6.5%. The expected escalation during the given period can be linked to several factors such as an increasing demand for new treatments, a growing elderly population, the introduction of personalized medicine, a focus on non-drug interventions, and the emergence of biologics and innovative therapies. The forecast period is also poised to witness trends such as the use of alternative therapies and mind-body practices, a broader field of research in intestinal health, the emergence of patient-responsive care models, targeted advertising to enhance gerd awareness, and the utilization of digital health resources.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp
What are the Key Market Players in Gastroesophageal Reflux Disease Therapeutics Market and How They’re Evolving?
Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
What Are the Primary Growth Drivers in the Gastroesophageal Reflux Disease Therapeutics Market?
The rising occurrence of gastroesophageal reflux disease is anticipated to stimulate the expansion of the gastroesophageal reflux disease therapeutics market in the future. This chronic ailment is distinguished by the reversal flow of stomach acid into the esophagus, leading to symptoms like heartburn, regurgitation, and potential complications. The therapeutics for gastroesophageal reflux disease (GERD) aid in lessening and managing acid reflux symptoms by neutralizing gut pH, managing inflammation, and enhancing esophageal function. As per a report by WebMed, a US-based health news and information provider, in September 2022, over 60 million American adults experience heartburn at least once a month, and more than 15 million endure it daily. Furthermore, the National Library of Medicine, a US federal medical library, shared statistics in July 2022 indicating that GERD is one of the frequently diagnosed digestive disorders in the United States, having a 20% prevalence rate. This significant prevalence causes a major economical strain due to direct and indirect costs and also affects quality of life. Hence, the rising incidence of gastroesophageal reflux disease is predicted to fuel the expansion of the gastroesophageal reflux disease therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp
What Are the Leading Segments in the Global Gastroesophageal Reflux Disease Therapeutics Industry?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Super markets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
What Are the Key Market Trends in the Gastroesophageal Reflux Disease Therapeutics Industry?
The gastroesophageal reflux disease therapeutics market is primarily being driven by product innovations. Major competitors in the market are seeking to develop inventive medicines to maintain their dominance. For example, Phathom Pharmaceuticals, a biopharmaceutical company based in the US, introduced VOQUEZNA (vonoprazan), a potassium-competitive acid blocker, in November 2023. This was approved for treating and maintaining all grades of erosive esophagitis and for relieving heartburn related to both erosive and non-erosive GERD. Clinical trials of the drug showed promising results with a healing rate of 93% for patients who received the 20 mg dosage, which is significantly higher than the 85% healing rate achieved with the standard proton pump inhibitor (PPI) lansoprazole.
Access The Full Report Here:
What Is the Regional Outlook for the Gastroesophageal Reflux Disease Therapeutics Market?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12058
This Report Delivers Insight On:
1. How big is the gastroesophageal reflux disease therapeutics market, and how is it changing globally?
2. Who are the major companies in the gastroesophageal reflux disease therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the gastroesophageal reflux disease therapeutics market right now?
4. Which products or customer segments are growing the most in the gastroesophageal reflux disease therapeutics market?
5. What factors are helping or slowing down the growth of the gastroesophageal reflux disease therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
